Patents Examined by George W Kosturko
  • Patent number: 11590147
    Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: February 28, 2023
    Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
  • Patent number: 11584754
    Abstract: In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: February 21, 2023
    Assignee: William Marsh Rice University
    Inventors: Kyriacos C. Nicolaou, Derek Rhoades, Soundarapandian M. Kumar, Manas R. Pattanayak, Manjunath Lamani
  • Patent number: 11576919
    Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: February 14, 2023
    Assignee: Genentech, Inc.
    Inventor: Kui Lin
  • Patent number: 11547711
    Abstract: Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: January 10, 2023
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Christian Hassig, Ryan Hansen, Snezana Milutinovic, Jason Christiansen, Zachary Hornby, Sudhir Chowdhry, Anthony Celeste, Kristen Turner, Deepti Wilkinson
  • Patent number: 11529339
    Abstract: Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 20, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Michael D. Amatangelo, Chad Bjorklund, Anjan Thakurta, Xiankang Hong, Mariana Cota
  • Patent number: 11523987
    Abstract: Provided here are new ophthalmological methods for the treatment or prophylaxis of ocular bacterial infections and related conditions comprising delivering an effective amount of an ophthalmologically suitable composition comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, methods comprise delivery of the composition by injection. In aspects, the delivered compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension and may also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or, an agent that provides both functions.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: December 13, 2022
    Assignee: Somerset Therapeutics, LLC
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan, Ojas Prakashbhai Doshi
  • Patent number: 11510919
    Abstract: The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Herein is demonstrated a strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner superior to combinations with MEK inhibitors.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: November 29, 2022
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Jessie Peh, Matthew Boudreau
  • Patent number: 11510410
    Abstract: The disclosure provides a pediculicidal composition comprising a metal chelating agent; a carrier vehicle comprising water and an activating solvent system comprising an alcohol and a hydrocarbon. The carrier vehicle may be in the form of a solution, a cream, an ointment, a foam, a spray, an emulsion or a gel. The disclosure also provides method for use of a pediculicidal composition to treat human head lice and their eggs and methods for controlling head lice infestation.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: November 29, 2022
    Inventors: Ronald Harding, Lewis David Schulz, Vernon Morrison Bowles
  • Patent number: 11512055
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: November 29, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Yinfa Yan, Minsheng Zhang, Dong Liu, Fengqi Zhang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Patent number: 11504365
    Abstract: Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.
    Type: Grant
    Filed: April 14, 2022
    Date of Patent: November 22, 2022
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Michael P. Bailey, Michael N. Needle
  • Patent number: 11505550
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: November 22, 2022
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Patent number: 11478001
    Abstract: Provided herein are methods of administering pre-operative beverage compositions to be ingested by a patient prior to administration of anesthesia or sedation in preparation for a safe induction of anesthesia or sedation in a patient before surgery. The beverage has one or more carbohydrates, wherein the total Calories available from the carbohydrates is at least about 200 and wherein the one or more carbohydrates are the sole source of significant Calories in the beverage, an acid, in a quantity sufficient to result in a pH of at least about 3.7 to about 4.5 and to enhance the shelf life and flavor of the beverage, a central nervous system (CNS) stimulant that is also a cerebro-vasoconstrictor, a sweetener, and water. The beverage composition, when ingested at least about two hours prior to administration of anesthesia or sedation is effective to relieve one or more symptoms associated with prolonged fasting.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 25, 2022
    Assignee: CLEARFAST INC.
    Inventor: M. Lou Marsh
  • Patent number: 11478483
    Abstract: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of Quetiapine or derivative thereof. The compositions include an effective amount of Quetiapine or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: October 25, 2022
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 11453660
    Abstract: The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: September 27, 2022
    Inventors: Guido Kurz, Juan Camacho Gómez
  • Patent number: 11440921
    Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: September 13, 2022
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Andrea Bauer, Nandkumar Nivritti Bhogle, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Kostas Saranteas, Michael Joseph Sizensky, Harold Scott Wilkinson, Haitao Zhang
  • Patent number: 11433077
    Abstract: Disclosed is an inhibitor of calcineurin of the setron family for use for treating hearing loss in a subject in need thereof.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 6, 2022
    Assignee: SENSORION
    Inventor: Jonas Dyhrfjeld-Johnsen
  • Patent number: 11426409
    Abstract: The present invention includes methods of treating or preventing HER-driven drug-resistant cancers. In certain embodiments, the cancer comprises lung cancer.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 30, 2022
    Assignee: The Regents of the University of Colorado
    Inventor: Robert C. Doebele
  • Patent number: 11414414
    Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 16, 2022
    Assignee: SHANGHAI XUANCHUANG BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Guobin Ren, Jinyao Chen
  • Patent number: 11407999
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating an angiogenesis-related ocular disease comprising an inhibitor of MCT expression or MCT activity as an active ingredient, and it can effectively prevent or treat an angiogenesis-related ocular disease without affecting the normal function of VEGF required for maintaining homeostasis of choriocapillary and visual cells, by specifically inhibiting only VEGF secreted by macrophages, different from conventional treatment.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 9, 2022
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Seung Hyeok Seok, Juha Song, Ki Hwang Lee
  • Patent number: 11400087
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: August 2, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia